NCT04263402

The Efficacy of Different Hormone Doses in 2019-nCoV Severe Pneumonia

An Open, Prospective/Retrospective, Randomized Controlled Cohort Study to Compare the Efficacy of Different Hormone Doses in the Treatment of 2019-nCoV Severe Pneumonia

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Tongji Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

At present, there is no specific and effective antiviral therapy.In this study, an open, prospective/retrospective, randomized controlled cohort study was designed to compare the efficacy of different hormone doses in the treatment of 2019-nCoV severe Pneumonia.This study explores effective treatment programs for 2019-nCoV severe pneumonia and provides a reliable evidence-based basis for the treatment.

Conditions

• 2019-nCoV Severe Pneumonia

Interventions

Type	Name	Description
DRUG	Methylprednisolone	Patients in the Group I will receive basic symptomatic supportive treatment,plus methylprednisolone(\<40mg/d intravenous drip for 7 days).
DRUG	Methylprednisolone	Patients in the Group II will receive basic symptomatic supportive treatment,plus methylprednisolone(40\~80mg/d intravenous drip for 7 days).

Timeline

• Start date: 2020-02-01
• Primary completion: 2020-06-01
• Completion: 2020-07-01
• First posted: 2020-02-10
• Last updated: 2020-03-17

Locations

1 site across 1 country: China